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The relationship between environmental toxins and cancer has plagued 
scientists for more than a century. School of Public Health researcher 
Patricia Foster, Ph.D., is investigating how chemical carcinogens cause 
mutations in bacterial DNA. See story on page 3. 
Jerome O. Klein, M.D., examines the ear of a young patient. Klein and his colleagues are looking 
for factors that may increase a child's risk of ear infections. (Photo by James P. Dwyer) 
Long-term effects of middle ear 
infections explored by research team 
Middle ear infections are tantamount 
to a price most of us pay for negoti-
ating the first three years of life. 
Jerome O. Klein, M.D., a professor 
of pediatrics at Boston University 
School of Medicine, and his asso-
ciates, in a study several years ago 
of 2,500 Boston children, found that 
71 percent of the youngsters suf-
fered at least one such infection in 
the first 36 months of life. Nearly 
half that group, moreover, had three 
or more infections. 
Similar figures probably apply 
nationally, said Klein, noting that 
middle ear infections are the most 
common reason for doctors' visits 
among children three years of age 
and under. 
Dealing with the infections them-
selves is seldom difficult. "With an 
appropriate antibiotic, children will 
have remission of their acute 
symptoms-mainly fever and 
earache-within two or three days," 
said Klein, who heads the Division of 
Pediatric Infectious Diseases at Bos-
ton City Hospital. 
The infections, however, can leave 
behind fluid in the middle ear. 
continued on page 5 
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New technique 
yields genetic link, 
diagnostic tests for 
Alzheimer's, Down 
A genetically-related cause for Down 
syndrome (DS) and Alzheimer's dis-
ease (AD) has been postulated by 
scientists in the past but, until now, 
research in the area has received lit-
tle support. Recent reports by 
National Institutes of Health 
researchers and others, however, 
have cited and upheld the hypoth-
esis that was first suggested two 
years ago by Miriam Schweber, 
Ph.D., an assistant research pro-
fessor of biochemistry at Boston Uni-
versity School of Medicine, that both 
Down and Alzheimer's are the result 
of a quantitative change in the DNA 
that normally exists on chromosome 
21. 
To show this connection, 
Schweber has invented a new 
method that accurately measures 
and compares minute amounts of 
genetic material from various tissues, 
including blood. Her technique and 
device for carrying it out may pro-
vide researchers with a reliable diag-
nostic test for DS very early in preg-
nancy. It offers a diagnostic test at 
present for Alzheimer's and may 
offer a presymptomatic test as well. 
The technique of DNA measure-
ment already has proved effective in 
detecting Down from non-Down tis-
sues. In a similiar way, she hopes 
continued on page 2 
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Genetic link... 
continued from page 1 
the test will prove as accurate for 
people with Alzheimer's and, by 
extension, for any condition involving 
quantitative changes in DNA. For 
example, patients with problems 
resulting from extra sex chromo-
somes (XXY or XO) would be likely 
candidates for this sort of screening. 
Individuals born with Down syn-
drome are characterized by mental 
deficiency and often abnormalities of 
other organs, especially the heart. 
Alzheimer's is a form of degenerative 
dementia in adults characterized by 
progressive memory loss and per-
sonality changes. It has been esti-
mated that Alzheimer's affects more 
than three million people in the 
United States. 
As a departure point for her stud-
ies, Schweber reviewed the reports 
of autopsies on 200 individuals over 
age 35 with Down syndrome and 
600 under age 35. In every case, 
the studies revealed the same 
abnormal structural changes in the 
brain found in victims of Alzheimer's--
the same so-called plaques and 
tangles-and also, although less con-
clusively, the same biochemical 
alterations. 
"Laboratory findings have indi-
cated that all individuals with Down 
syndrome eventually get Alzheimer's, 
although they don't always express it 
behaviorally," said Schweber. "This 
has led to the idea that the effect of 
aging in persons with Down syn-
drome produces the clinical phe-
nomenon called Alzheimer's. To me, 
the evidence of neuropathology and 
biochemical studies meant that the 
two conditions could have a common 
cause." 
However, two obvious questions 
arise from her assertion: If all per-
sons with Down eventually get Alz-
heimer's, why aren't persons with 
Down syndrome all demented at the 
time of death, and why don't all Alz-
heimer's victims have Down as well? 
Miriam Schweber, Ph.D., has found a genetic 
link between Alzheimer's disease and Down 
syndrome. (Photo by John Thompson) 
In Schweber's opinion, it is irrelevant to 
apply traditional criteria for Alzheimer's-
type dementia to Down syndrome 
because AD involves a loss of abilities 
that a person with Down never had. 
The progression of the dementia, there-
fore, usually is masked in DS. How-
ever, according to Schweber, about 25 
percent of adults with Down syndrome 
actually are classified as demented at 
time of death, but they are only identi-
fied as such because the symptoms 
have become so severe that they qual-
ify as the terminal stage of Alzheimer's, 
characterized by violent personality 
changes, incontinence, total dis-
orientation and even the inability to 
move about. 
The answer to why not all Alz-
heimer's victims have Down syndrome 
is the subject of Schweber's current 
studies. There are two types of Down 
syndrome, she explained: Trisomy 
Down, in which there are three full cop-
ies of chromosome 21 instead of the 
normal two; and translocation Down, in 
which there is a triplication of a limited 
section of genetic material from 
chromosome 21 . 
"I think that Alzheimer's is due to 
three copies of a small segment of 
DNA within that limited triplication. 
Therefore, all Down individuals would 
develop Alzheimer's but not the 
reverse. We have to look closer now to 
see how big the area of triplication is 
and how it differs in different forms 
of Alzheimer's," she said. 
Schweber has tested 15 Alz-
heimer's patients so far, including 
examples of early- and late-onset, 
sporadic and familial cases. Samples 
of tissue from these people show 
that in all categories there is triple 
the amount of DNA on chromosome 
21 in a small section near the Down 
location. 
What enables Schweber to get this 
"closer look" has been her occupa-
tion for much of the past five years. 
She calls the result, unveiled in April 
at the annual meeting of the Ameri-
can Academy of Neurology, "Miri-
am's Monstrosity." The device, which 
stands six feet high, enables 
Schweber to pre-image a standard 
of measurement onto film. The sys-
tem has been patented by BUSM. 
"Our technique allows one for the 
first time to look at an image of DNA 
on film and tell if its an accurate rep-
resentation of the amount of material 
there," Schweber said. 
Essentially, the method is a mod-
ification of the Southern Blot tech-
nique for measuring DNA. A sample 
of raw DNA from a particular tissue 
is chopped into pieces using 
enzymes of different sizes. The mix-
ture is put onto a gel and subjected 
to electrophoresis, which causes the 
material to separate according to 
size. By next inserting pieces of the 
chopped up, or recombined, DNA 
into bits of bacterial DNA called plas-
mids, one can compare quantities of 
DNA on different chromosomes. 
Using blood samples obtained from 
veterans hospitals, Schweber has 
accurately distinguished individuals 
with Alzheimer's from normal 
patients. 
The next step, said Schweber, is 
to continue testing several hundred 
more samples for the Alzheimer's 
defect, and to refine her design in 
order to make the test less cumber-
some, more accessible and less 
costly. "I'd like it to be available to 
any physician who wants to do a 
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SPH researcher looking for 
clues to cancer in bacterial DNA 
screening, although I don't think it 
will be appropriate in an office set-
ting. The technique is rather sophis-
ticated and requires more expertise 
than a normal Southern Blot," she 
said. Schweber is in the process of 
setting up programs in conjunction 
with several hospitals. 
As the early stages of Alzheimer's 
are extremely difficult to diagnose, 
presenting physicians with a bewil-
dering array of symptoms, it often 
takes several years to determine if 
the problem is really Alzheimer's or 
some other, treatable problem. 
Schweber's procedure has the 
potential to offer early diagnosis of 
people at risk for the illness. Physi-
cians then will know if the disease is 
treatable and can plan treatment 
strategies at a time when they might 
do some good. "There are more 
than 100 forms of dementia, some 
treatable, some not. This test could 
be used to rule out Alzheimer's if 
nothing else," said Schweber. "Do 
families want to know? It's up to 
them, but at least it's available. 
"Alzheimer's is clearly a complex 
disease," said Schweber. "Right 
now, a completely certain diagnosis 
can only be made with an autopsy, 
which doesn't help the sufferer 
much, nor is it useful in looking for 
treatments." 
Schweber's work has been sup-
ported by a grant from the Retire-
ment Research Foundation and an 
Allied-Signal Corp./Alzheimer's and 
Related Disorders Association Fac-
ulty Scholar Award. Her colleagues 
in the research include postdoctoral 
colleagues Ruth Shiloh, Ph.D., and 
Ziva Ben-Neriah, M.D., of Jerusalem, 
Israel, and laboratory technician 
Clare Tuson. 
--Caroline H. Lupfer 
Suggested Further Readings 
1. Schweber, M.: Interrelation of Alzheimer's 
Disease and Down Syndrome. New Per-
spectives on Down Syndrome, Paul H. 
Brookes Publishing Co., 1985. 
2. Schweber, M.: Interrelations of Down Syn-
drome and Alzheimer's disease, arcfacts, 
August 1986. 
In 1775, British surgeon Percivall 
Pott discovered a high incidence of 
scrotal cancer in chimney sweeps, 
and identified the culprit as soot. 
The short article he later wrote on 
the subject was one of the first 
attempts at linking the human dis-
ease with chemical carcinogens. 
Since then, scientists have scruti-
nized the relationship between a 
myriad of suspected environmental 
toxins and cancer. One of these sci-
entists is Patricia Foster, Ph.D., an 
assistant professor of environmental 
health at Boston University School of 
Public Health, who has spent the 
last six years looking for clues to the 
cause of cancer in the DNA of the 
bacterium Escherichia coii. Accord-
ing to Foster, understanding how a 
chemical carcinogen induces muta-
tions (a single mutation can change 
a normal gene into its oncogenic 
derivative) may shed light on the 
etiology of cancer. 
Two of the chemicals involved in 
Foster's research, the insecticide 
ethylene dibromide (EDB) and the 
chemotherapeutic agent cis -
diamminedichloroplatinum-ll ( cis-
-Pt), are known carcinogens, and 
Foster is studying their effect on E. 
coli DNA. EDB also is used as an 
antiknock additive in leaded gasoline 
and as an industrial solvent. Her 
investigations focus on four main 
questions: What DNA lesions are 
induced? Which give rise to muta-
tions? How are the lesions repaired? 
And what mutations result? 
According to Foster, 80 to 90 per-
cent of chemical carcinogens cause 
mutations in bacteria; therefore bac-
teria provide good model systems 
for her study. "My basic feeling is 
tvhat the kinds of damage that arise 
in DNA are not specific to any par-
ticular organism," said Foster. 
"There is quite a bit of experimental 
evidence indicating that the DNA is 
essentially the same and the kinds 
of DNA damage you see in bacteria 
are exactly the same as those in higher 
organisms. So the research is aimed at 
understanding what damage there is 
and how that damage is repaired." This 
is important, Foster added, because 
much of the DNA repair activity is the 
same in bacteria as in mammals. 
DNA lesions, like crosslinks and base 
deletions, arise from three pathways: 
direct interaction of the chemical with 
the DNA, the interaction of a metabo-
lically activated chemical with the DNA 
and the repair of the initial lesion cau-
sed by the chemical. Each of these 
pathways leads to recognizable bio-
logical effects. Foster has developed 
what she calls a mutagenic "fingerprint" 
to identify the DNA lesions that give 
rise to mutations. She does so by 
exposing E. coli to a mutagen and 
determining the effects of specific 
repair defects on the mutations that 
result. She then can confirm the results 
biochemically. According to Foster, 
"This knowledge can be applied to 
higher organisms where the biological 
endpoint may not be the same, but the 
DNA lesion is likely to be." 
Foster begins her research with a 
known carcinogen, like cis-Pt. The 
mechanism by which cis-Pt and many 
other chemotherapeutic agents work is 
by killing the cancer cells at a faster 
rate than the normal cells. But patients 
using these agents run the risk of 
developing second-site cancers. "The 
cancer cells are dividing faster, which 
means they are replicating their DNA 
faster," said Foster. "So if you use a 
DNA damaging agent, you can achieve 
that differential toxicity. But over time, 
you're causing DNA damage and that 
in itself is a carcinogenic process." 
By using bacteria that are defective 
in repair enzymes-enzymes that can 
be eliminated genetically-Foster can 
see the changes that occur in the DNA 
when cis-Pt is introduced. Once you 
know how the cis-Pt molecule is 
interacting with the DNA, said Foster, 
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you can identify what types of muta-
tions are induced by sequencing the 
DNA. "So now I have a good idea of 
how the chemical is interacting, what 
the lesion is and what the result is. 
The next step is to break them (the E. 
coli) open, get the DNA out and find 
the lesion," said Foster. 
According to the scientist, cis-Pt is 
a bifunctional agent: It can link two 
DNA bases together either in the 
same strand or across the strands of 
the double helix. "My suspicion is that 
when it's linking in one strand, that's 
mutational and when it's linking acr-
oss the strands, that's lethal," she 
said. "I want to find out what kind of 
mutations you get under those two dif-
ferent conditions," she said. In other 
words, Foster wants to know if, for 
example, two mutations occur 
because two bases are tied up or if 
base deletions occur when a DNA 
strand loops out. 
"One would like to figure out if 
there's a way to decrease the toxicity 
and potential for causing second-site 
cancer but maintain the chemoth-
erapeutic activity," she said. 
Foster chooses the chemicals in 
her research for two reasons. One is 
Patricia Foster, Ph.D., hopes to find clues to 
cancer in the DNA of E. coii. (Photo by 
Bradford F. Herzog) 
that many of them, like cis-Pt, 
cause "interesting types of damage." 
Another is that, like EDB, they are 
important environmental carcin-
ogens. As a pesticide, EDB is used 
in grain storage and in orchards, 
and, according to Foster, has shown 
up in produce in grocery stores. 
Foster's EDB research also is 
applicable to human cancers, espe-
cially where occupational hazards 
are concerned. EDB is a carcinogen 
in rats, which suggests that it causes 
cancer in humans as well. According 
to Foster, the compound is not 
active until it is metabolically proc-
essed, usually in the liver. There are 
two possible pathways in humans, 
each using different enzymes, by 
which EDB may be activated into 
what is called the "ultimate carcin-
ogen," capable of directly interacting 
with the DNA. The other pathway 
may detoxify the chemical. 
Using the bacteria, Foster can test 
which of these pathways processes 
the EDB to the active compound. If 
the bacteria has only one of the 
pathways and mutations arise when 
EDB is introduced, then it's likely 
that the same pathway in humans 
will activate the compound. "I've 
been working for four years to be 
able to do these analyses very 
rapidly and easily," said Foster. 
It's important to know which path-
way activates the EDB because cer-
tain drugs, like those used to curb 
extreme forms of alcohol abuse, 
depress one route, said Foster. 
Therefore, if this is the detoxifying 
pathway, then anyone working with 
the chemical should not be on the 
drug. 
Foster believes she can extrapo-
late from her research because the 
repair processes are so similar in 
bacterial and human DNA. In fact, 
she said, "I think bacteria are more 
sophisticated than higher organisms 
in this particular aspect, because 
they're living in the fast lane. Things 
have got to go right; they have to 
repair their damage. They don't have 
compartments where cells can be 
safely destroyed, because they are the 
cell. So, they've evolved a lot of capa-
bilities that higher organisms farm out 
to different cell systems." 
Foster emphasizes that hers is basic 
research, the primary goal of which is 
to understand just how the DNA dam-
age and repair systems work. "Eventu-
ally you turn to mammalian cells and 
ask, 'are you getting the same type of 
damage and lesion and is it activating 
an oncogene?' That's the eventual goal 
of all of this-that you want the whole 
thing, from chemical to oncogene, to 
make sense." 
The next step for Foster, whose 
research is funded by grants from the 
National Cancer Institute, is to study 
eukaryotic systems, particularly yeast. 
A lot of research has been done on 
yeast, an organism containing DNA 
structures that are absent in E. coli, 
such as chromosomes, histones and 
oncogenes. "If I think about what the 
ultimate application is," she said, "it 
would be to know, in the face of envi-
ronmental insult, how animals are cop-
ing with DNA damage. And then to 
apply that knowledge to prevent or 
reverse the damage." 
--Cynthia A. Koury 
Suggested Further Readings 
1. Foster, P.L et al: Creation of a test plasmid for 
detecting G C-to-T A transversions be chang-
ing serine to arginine in the active site of B-
lactamase. J Bacteriology 169: 1987. 
2. Foster, P.L, and Davis, E.F.: Loss of an 
apurinic/apyrimidinic site endonuclease 
increases the mutagenicity of A/-methyl- N'-
nitro- N -nitrosoguanidine to Escherichia coli. 
Proc Natl Acad Sci. 84: 1-6, 1987. 
3. Foster, P.L, and Eisenstadt, E.: Induction of 
transversion mutations in Escherichia coli by N 
-methyl- A/'-nitro- A/-nitrosoguanidine is SOS 
dependent. J Bact. 163: 213-220, 1985. 
4. Eisenstadt, E.: Analysis of Mutagenesis in 
Escherichia coli and Saimonella typhimurium . 
Escherichia coii and Saimonella typhimurium , 
Cellular and Molecular Biology. Neidhardt, F.C. 
ed. American Society for Microbiology, 1987. 
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Middle ear infections... 
continued from page 1 
Though the fluid usually dissipates 
fairly rapidly, in some cases the fluid 
may last several months. When that 
occurs, added Klein, problems may 
ensue. 
"Fluid in the middle ear reduces 
sound conduction, on average, by 
about 25 decibels," he said. "As a 
British investigator has described it, 
for a young child who's just starting 
to acquire language skills, that's 
equivalent to trying to learn a foreign 
language with your fingers in your 
ears." 
There is evidence that such hear-
ing impairments interfere with learn-
ing. Part of the data comes from 
follow-up studies of children who 
were involved in the original middle 
ear study by Klein and his asso-
ciates. 
Roughly 200 of those youngsters 
were tested at around the time of 
their third birthdays for language 
capabilities. "Many of the children 
who had had a lot of ear disease 
had significantly lower scores on 
selected tests, including those for 
vocabulary, speech production and 
speech comprehension," said the 
investigator. Especially affected were 
youngsters from higher-income fami-
lies, and those who had infections 
during the first year of life. 
When the same children were 
tested again at around their seventh 
birthdays, the investigators found 
that children who had suffered 
repeated ear infections in the first 
three years of life still scored lower 
than their peers even though few 
were affected by new infections after 
they reached age 3. 
Though such findings strongly 
suggest a need to treat the pers-
istant middle ear fluid, the most com-
mon approach to treatment is contro-
versial. The approach involves mak-
ing a tiny incision in the eardrum, 
which is part of the outer wall of the 
middle ear, and inserting a small, 
short plastic tube that allows the 
fluid to drain. 
"There are widely differing opinions 
about that procedure in the field," 
noted Klein. "Many otolaryngologists 
feel that since it is an operation, and 
involves anesthesia, it should be done 
sparingly." In fact, however, there are 
roughly 500,000 such procedures per-
formed each year in the nation. 
Klein and BUSM colleagues, David 
Teele, M.D., an associate professor of 
pediatrics, and Stephen Pelton, M.D., 
an associate professor of pediatrics, 
have joined with a group from Chil-
dren's Hospital in Boston in a new 
study headed by Gerald B. Healy, 
M.D., a professor of otolaryngology, of 
2,000 children that may help resolve 
the issue of when surgery is justified. 
The study is sponsored by the National 
Institute of Neurologic Diseases and 
Communicative Disorders and Stroke. 
The investigators are concerned with 
whether it makes sense to start treating 
more youngsters during their first year 
of life. Relatively few in that age group 
currently undergo surgery related to ear 
infections. 
The study, which began in early 
1986, involves monitoring every child 
who visits one of four designated 
medical-care centers: a primary care 
center at Boston City Hospital, the East 
Boston Neighborhood Health Center, 
and private pracitices in Weston and 
Holliston, two relatively affluent sub-
urban towns west of Boston. 
The diversity of settings reflects an 
effort to explore the apparent connec-
tion between socio-economic factors, 
learning problems and middle ear infec-
tions. 
"It may be that children from lower 
socio-economic backgrounds have a lot 
of different factors that are interfering 
with their learning, so the hearing loss 
is less significant overall than for chil-
dren from more affluent backgrounds," 
explained Klein. "In our study, we hope 
to clarify whether that's really what's 
going on." 
The study also is examining other 
issues related to the long-term effects 
of middle ear infections. Among them: 
What are the major factors that tend to 
increase a child's risk of acquiring a 
middle ear infection? To what extent 
do the effects of the fluid persist 
after the fluid is gone? And, is it pos-
sible to reduce the risks of recurrent 
infections? 
Klein's earlier study pointed to a 
number of factors that may increase 
a child's risk of ear infections. 
One was the fact that suscep-
tibility seems to run in families. Klein 
believes this probably reflects inher-
ited anatomical, physiologic or 
immunologic characteristics. He 
noted that the passage between the 
nose and the middle ear is generally 
wide and comparatively flat in young 
children anyway, thus allowing infec-
tious agents to travel with relative 
ease from the nose and upper respi-
ratory tract into the middle ear. He 
suspects that some children inherit a 
configuration that makes that pas-
sageway even more conducive than 
usual to movement of viruses and 
bacteria. 
Another factor that influenced risks 
of middle ear infections was breast-
feeding. Children who had been 
breast-fed during their first year of 
life tended to have fewer middle ear 
infections during that period than 
those who were not breast-fed. 
"This tells us that breast milk 
probably transmits some type of 
immunological substance from the 
mother to the child," said Klein. "The 
key point is that it seems to confer 
protection during the first year." The 
study also indicated that children 
who had an episode early in the first 
year of life were more likely than 
their peers to suffer multiple infec-
tions during early childhood. 
In the new study, Klein and his 
associates are planning to explore 
other potential risk factors not fully 
explored in the earlier research. 
Specifically, they want to find out if 
youngsters in day-care settings have 
a higher risk of middle ear infections 
than those who are cared for at 
home, and also if exposure to 
tobacco smoke increases a child's 
infection risks. 
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"There's evidence that smoke, or at 
least some of its constituents, affects 
mucosa that lines the respiratory tract, 
including the middle ear, and may 
damage some of its clearance mech-
anisms," noted Klein. Among such 
mechanisms, he added, are the cilia, 
tiny hairs that can sweep away bac-
teria or viruses by means of a wave-
like motion. 
As the investigators seek to pin-
point additional risk factors, they also 
are testing a preventive therapy for 
children deemed at high risk for multi-
ple infections. 
The children involved are those 
who suffer an infection at any time 
during the first year of life. The drugs 
to be used, said Klein, are a sulfan-
amide (sulfisoxazole) and a penicillin 
(Ampicillin). If an infected child's par-
ents consent, each antimicrobial drug 
Klein believes that susceptibiiity to ear infec-
tion may reflect inherited anatomicai char-
acteristics. (Diagram courtesy of BUSM Edu-
cationai Media) 
will be administered in a modified 
dose to one-third of the children 
enrolled in the study for up to six 
months. The other third will serve as 
a control group, getting a placebo 
instead. 
"We think we may be able to 
reduce the colonization rate of the 
infectious organisms in the respi-
ratory tract, and by so doing, lower 
the risks facing these children," said 
Klein. 
The third major airn of the study is 
to further investigate the effects of 
persistent middle ear fluid on learn-
ing. All of the youngsters will be 
given speech, language and cog-
nitive tests on their first, second and 
third birthdays, and their performan-
ces will be considered in light of 
their disease patterns through that 
period. One goal, said Klein, is to 
see if there are critical periods when 
otitis media-related hearing problems 
have an especially serious impact on 
children's acquisition of language 
skills. 
"If we find that infections in the 
first year of life don't have long-term 
consequences, that would suggest 
there is little need for an aggressive 
approach to treatment," noted Klein. 
"On the other hand, if the infections 
during this period are associated 
with learning deficiencies in the early 
years of life, that might indicate that 
we should be aggressively treating 
infants with sustained middle ear 
effusion." 
--Richard P. Anthony 
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